What Synairgen’s anti Covid drug is and how it works
Phase 3 trial in the United States of the anti Covid-19 drug SNG001, developed by the British Synairgen
More than a year after the start of the Covid-19 pandemic, we still do not have a dedicated drug for the care and treatment of patients infected with Covid-19. However, there are several ongoing trials.
In America, the phase 3 trial of SNG001, an inhalation drug from the British Synairgen, kicks off today. All the details.
THE EXPERIMENTATION
Synairgen plc announced that the phase 2/3 trial of the inhaled drug SNG001 has begun on Monday, February 15, 2021, within the Activ-2 study. Treated patients have mild to moderate Sars-Cov-2 symptoms that do not yet require hospitalization.
ACTIV
Activ, the program in which the experimentation of the new hypothetical treatment against Covid has been included, is a public-private partnership born with the aim of developing a coordinated research strategy to accelerate the development of drugs and vaccines against coronavirus.
ACTIV-2 is sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), the American Institute of Public Health, and is led by the NIAID-funded AIDS Clinical Trials Group (ACTG).
PHASE 2 STUDIES
The inclusion in the program took place following the results of phase two of the double-blind trial of the drug, which ended on 20 July 2020. The study, called SG016 (EudraCT: 2020-001023-14), involved 221 patients, 101 patients treated in hospital and 120 patients treated in a home setting. The primary endpoint showed that the odds of improvement across the OSCI scale for patients who inhaled SNG001 were more than twice that of the placebo group.
THE DRUG
The drug harnesses the power of interferon beta (IFN-beta), a naturally occurring protein, which orchestrates the body's antiviral responses.
“There is evidence that a deficiency in the lung's IFN-beta production could explain the increased chance of some patients developing severe lung disease,” Synairgen explains.
SYNAIRGEN
Synairgen, a drug research and development company, founded by the University of Southampton professors Stephen Holgate, Donna Davies and Ratko Djukanovic, has developed the anti-Covid treatment being tested in America.
The company, the website reads , is mainly focused on therapies for the treatment of Covid-19, severe asthma, COPD, and other respiratory diseases. Its main drug is SNG001.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/cose-e-come-funziona-il-farmaco-anti-covid-di-synairgen/ on Mon, 15 Feb 2021 14:22:43 +0000.